ADVERTISEMENT

Wow! Another aids board.

NOV 6 2020


Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study

This study aims to determine the effectiveness of Ivermectin when administered as pre-exposure prophylaxis for COVID-19.

Result: 73.3% (44 out of 60) subjects in control group were positive for COVID-19, whereas only 6.9% (4 out of 58) of the experimental group were diagnosed with COVID-19 (p-value < 0.05).

Conclusion: Ivermectin, an FDA-approved, safe, cheap and widely available drug, should be subjected to large-scale trials all over the world to ascertain its effectiveness as pre-exposure prophylaxis for COVID-19.

 
ADVERTISEMENT
ADVERTISEMENT